Jane Street’s Keros Therapeutics KROS Stock Holding History

Jane Street’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131K	Sell	11,900 -20,500	-63%	-$317K	﹤0.01%	10480
2025 Q4	$660K	Sell	32,400 -52,200	-62%	-$916K	﹤0.01%	7096
2025 Q3	$1.34M	Sell	84,600 -29,300	-26%	-$433K	﹤0.01%	5712
2025 Q2	$1.52M	Buy	113,900 +60,500	+113%	+$817K	﹤0.01%	4871
2025 Q1	$544K	Sell	53,400 -8,400	-14%	-$97.5K	﹤0.01%	6706
2024 Q4	$978K	Buy	61,800 +52,600	+572%	+$2.73M	﹤0.01%	5440
2024 Q3	$534K	Buy	9,200 +2,900	+46%	+$143K	﹤0.01%	7076
2024 Q2	$288K	Sell	6,300 -13,600	-68%	-$731K	﹤0.01%	7865
2024 Q1	$1.32M	Sell	19,900 -1,100	-5%	-$65.2K	﹤0.01%	4892
2023 Q4	$835K	Sell	21,000 -18,600	-47%	-$583K	﹤0.01%	5886
2023 Q3	$1.26M	Buy	+39,600	New	+$1.48M	﹤0.01%	4812
2023 Q1	–	Sell	-4,300	Closed	-$206K	–	9504
2022 Q4	$206K	Buy	+4,300	New	+$201K	﹤0.01%	7631
2022 Q2	–	Sell	-26,200	Closed	-$1.43M	–	10330
2022 Q1	$1.43M	Buy	+26,200	New	+$1.34M	﹤0.01%	5398

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Jane Street's KROS Position: Q1 2026 in Review

Jane Street reduced its Keros Therapeutics (KROS) stake by 73% in Q1 2026, selling an estimated $1.82M and leaving 44,457 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #8083.

Jane Street first reported a position in KROS in Q2 2020 and has held it in 15 quarters since. The position peaked at $3.49M in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Jane Street held 44,457 shares of Keros Therapeutics worth $491K as of Q1 2026.
Jane Street sold 117,552 Keros Therapeutics shares in Q1 2026, an estimated $1.82M.
Keros Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8083 holding.
Jane Street first reported a position in Keros Therapeutics in Q2 2020 and has held it in 15 quarters since.
Jane Street's Keros Therapeutics position peaked at $3.49M in Q3 2024.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.